Top

BMC Infectious Diseases

Published in:

Open Access 01-12-2015 | Research article

Demographic determinants of syphilis seroprevalence among U.S. blood donors, 2011–2012

Authors: Mark Andrew Kane, Evan Martin Bloch, Roberta Bruhn, Zhanna Kaidarova, Edward Laurence Murphy

Published in: BMC Infectious Diseases | Issue 1/2015

Abstract

Background

No cases of transfusion-transmitted syphilis have been described for over four decades. While there is mandatory transfusion screening for syphilis, the absence of transmission is in part ascribed to a low prevalence of syphilis in the blood donor population, the concomitant use of antibiotics in a high proportion of transfusion recipients, allied with poor survival of T. pallidum during refrigerated storage of blood products.

Methods

A cross-sectional retrospective data analysis was conducted to ascertain the prevalence of Treponema pallidum antibodies in U.S. blood donors by demography and geography. Routine blood donation testing data and demographics were extracted from the data warehouse of a large network of U.S. blood centers. Crude and adjusted prevalence of T. pallidum antibodies and active syphilis infection were calculated, and GIS mapping was used to illustrate geographic distribution.

Results

The prevalence of T. pallidum seropositivity and active syphilis in first time donors was 162.6 (95% CI 145.5-181.2) per 100,000 donors and 15.8 (95% CI 10.8-22.3) per 100,000 donors, respectively. The odds of T. pallidum seropositivity were significantly elevated in African American (OR = 18.9, 95% CI 14.2-25.2), and Hispanic (OR = 2.8, 95% CI 2.0-3.8) as compared to Caucasian donors. Similarly, the odds of active T. pallidum infections were significantly higher in African American (OR 15.0, 95% CI 7.0-32.3) and Hispanic (OR = 5.8, 95% CI 2.9-11.6) as compared to Caucasian donors. Syphilis seropositivity was associated with first time blood donation, increasing age, lower education, birth outside the US, and positive tests for HIV and HCV. Geographically, T. pallidum seropositivity was increased in southern and western regions of the US.

Conclusions

Given the low seroprevalence of syphilis in blood donors, continued screening remains debatable; however it may provide a public health benefit through surveillance of at-risk populations.

Singh AE, Romanowski B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev. 1999;12(2):187–209.PubMedPubMedCentral

Gardella C, Marfin AA, Kahn RH, Swint E, Markowitz LE. Persons with early syphilis identified through blood or plasma donation screening in the United States. The Journal of infectious diseases. 2002;185(4):545–9.CrossRefPubMed

Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion. 2001;41(8):1069–71.CrossRefPubMed

van der Sluis JJ, Onvlee PC, Kothe FC, Vuzevski VD, Aelbers GM, Menke HE. Transfusion syphilis, survival of Treponema pallidum in donor blood. I Report of an orientating study Vox sanguinis. 1984;47(3):197–204.CrossRefPubMed

Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080–99.CrossRefPubMed

van der Sluis JJ, ten Kate FJ, Vuzevski VD, Kothe FC, Aelbers GM, van Eijk RV. Transfusion syphilis, survival of Treponema pallidum in stored donor blood II Dose dependence of experimentally determined survival times. Vox sanguinis. 1985;49(6):390–9.CrossRefPubMed

Centers for Disease Control and Prevention: Sexually Transmitted Diseases (STDs) Syphilis – CDC Fact Sheet. Available at: http://www.cdc.gov/std/syphilis/STDFact-Syphilis-detailed.htm Accessed 8 August 2013.

Spinola SM, Orazi A, Arno JN, Fortney K, Kotylo P, Chen CY, et al. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. The Journal of infectious diseases. 1996;173(2):394–402.CrossRefPubMed

Wasserheit JN. Epidemiological synergy Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sexually transmitted diseases. 1992;19(2):61–77.CrossRefPubMed

10.

Fenton KA, Breban R, Vardavas R, Okano JT, Martin T, Aral S, et al. Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis. 2008;8(4):244–53.CrossRefPubMed

11.

Centers for Disease Control and Prevention: Sexually transmitted disease surveillance 2012. Available at: http://www.cdc.gov/std/stats12/surv2012.pdf Accessed 15 January 2015.

12.

Centers for Disease Control and Prevention: The National Plan to Eliminate Syphilis from the United States. 1999, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention: Atlanta, GA.

13.

Centers for Disease Control and Prevention: Together We Can: The National Plan to Eliminate Syphilis from the United States, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Editor. 2006: Atlanta, GA.

14.

Gottlieb SL, Pope V, Sternberg MR, McQuillan GM, Beltrami JF, Berman SM, et al. Prevalence of syphilis seroreactivity in the united states: data from the national health and nutrition examination surveys (NHANES) 2001–2004. Sex Transm Dis. 2008;35(5):507–11.CrossRefPubMed

15.

Zou S, Notari EP, Stramer SL, Wahab F, Musavi F, Dodd RY. Patterns of age- and sex-specific prevalence of major blood-borne infections in united states blood donors, 1995 to 2002: american Red cross blood donor study. Transfusion. 2004;44(11):1640–7.CrossRefPubMed

16.

Centers for Disease Control and Prevention: National Health and Nutrition Examination Survey 2003–2004 data documentation, codebook, and frequencies. Available at http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/L36_C.htm. Accessed 8 August 2013.

17.

Centers for Disease Control and Prevention: Centers for Disease Control and Prevention2010 Sexually Transmitted Disease Surveillance – Slides from STD Surveillance, 2010. Available at: http://www.cdc.gov/std/stats10/slides.htm Accessed 8 August 2013.

18.

Herbenick D, Reece M, Schick V, Sanders SA, Dodge B, Fortenberry JD. Sexual behavior in the United States: results from a national probability sample of men and women ages 14–94. The journal of sexual medicine. 2010;7 Suppl 5:255–65.CrossRefPubMed

19.

Centers for Disease Control and Prevention: 2011 Sexually Transmitted Disease Surveillance – P&S Syphilis by Sex and Sex Behavior. Available at: http://www.cdc.gov/std/stats11/syphilis.htm Accessed 8 August 2013.

20.

Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881–9.CrossRefPubMedPubMedCentral

21.

Thomas DL, Rompalo AM, Zenilman J, Hoover D, Hook 3rd EW, Quinn TC. Association of hepatitis C virus infection with false-positive tests for syphilis. The Journal of infectious diseases. 1994;170(6):1579–81.CrossRefPubMed

22.

Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev. 1995;8(1):1–21.PubMedPubMedCentral

Title: Demographic determinants of syphilis seroprevalence among U.S. blood donors, 2011–2012
Authors: Mark Andrew Kane
Evan Martin Bloch
Roberta Bruhn
Zhanna Kaidarova
Edward Laurence Murphy
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-015-0805-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Hepatitis B vaccine knowledge and vaccination status among health care workers of Bahir Dar City Administration, Northwest Ethiopia: a cross sectional study

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis

Ebola virus disease complicated with viral interstitial pneumonia: a case report

Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) and proteinuria predict severity of acute kidney injury in Puumala virus infection

Genetic diversity of medically important and emerging Candida species causing invasive infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials